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Oxysterols are cholesterol metabolites that serve
multiple functions in lipid metabolism, including
as liver X receptor (LXR) ligands. 27-hydroxycholes-
terol (27HC) is an abundant oxysterol metabolized
by CYP7B1. How 27HC impacts vascular health is
unknown. We show that elevations in 27HC via
cyp7b1 deletion promote atherosclerosis in apoe/
mice without altering lipid status; furthermore, estro-
gen-related atheroprotection is attenuated. In wild-
type mice, leukocyte-endothelial cell adhesion is
increasedby27HCvia estrogen receptor (ER)-depen-
dent processes. In monocytes/macrophages, 27HC
upregulates proinflammatory genes and increases
adhesion via ERa. In endothelial cells, 27HC is also
proadhesive via ERa, and in contrast to estrogen,
which blunts NF-kB activation, 27HC stimulates
NF-kB activation via Erk1,2 and JNK-depen-
dent IkBa degradation. Whereas 27HC adminis-
tration to apoe/ mice increases atherosclerosis,
apoe/;era/areunaffected. Thus, 27HCpromotes
atherosclerosis via proinflammatory processes
mediated by ERa, and it attenuates estrogen-related
atheroprotection. Strategies to lower 27HCmaycom-
plement approaches targeting cholesterol to prevent
vascular disease.
INTRODUCTION
Oxysterols aremetabolites of cholesterol that classically perform
multiple functions in lipid metabolism. They attenuate the
expression of transcription factors necessary for the activation
of genes within cholesterol supply pathways, they serve as li-
gands for the liver X receptors (LXR) a and b, they are substrates
for the synthesis of bile acids, and they function in reverse
cholesterol transport (RCT) to deliver sterols from peripheral
tissues to the liver. The most abundant oxysterol is 27-hydroxy-
cholesterol (27HC), which is synthesized by sterol 27-hydroxy-172 Cell Metabolism 20, 172–182, July 1, 2014 ª2014 Elsevier Inc.lase (CYP27A1) and metabolized by oxysterol 7a-hydroxylase
(CYP7B1) (Brown and Jessup, 1999; Li-Hawkins et al., 2000;
Russell, 2000; Tontonoz and Mangelsdorf, 2003).
The consideration of a potential impact of oxysterols on
vascular disease was initially prompted by the observation that
they are concentrated in atherosclerotic lesions. The most prev-
alent oxysterol in lesions is 27HC. Whereas circulating levels of
27HC in humans range from 150 to 730 nM, 27HC levels in
atherosclerotic lesions are two orders of magnitude higher
(Brown and Jessup, 1999). Circulating 27HC concentrations
are predictably elevated with hypercholesterolemia, and they
also increase with age (Brown and Jessup, 1999), particularly af-
ter the age of 30 (Burkard et al., 2007). However, studies of 27HC
in vascular health and disease, including work in animal models
as well as in humans, have yielded equivocal results (Tontonoz
and Mangelsdorf, 2003), and how 27HC influences vascular
well-being remains unknown.
In the present investigation, we sought to determine how
27HC impacts atherosclerosis. Recognizing that prior studies
have been difficult to interpret because of the close correlation
between 27HC and total cholesterol concentrations (Tontonoz
and Mangelsdorf, 2003), we have employed cyp7b1/ mice,
which have elevations in 27HC both in the circulation and in tis-
sues but entirely normal plasma cholesterol and triglyceride
levels (Li-Hawkins et al., 2000). To segregate the actions of
cholesterol and 27HC, we have crossed apolipoprotein E/
(apoe/) and cyp7b1/ mice to generate models in which
there is differing 27HC abundance in the setting of normocho-
lesterolemia, differing cholesterol abundance in the setting of
comparable 27HC levels, or differing 27HC abundance in the
setting of comparable hypercholesterolemia. We have discov-
ered that without altering lipid status, elevations in 27HC pro-
mote atherosclerosis. This is initially surprising because of the
known roles of oxysterols in RCT and as ligands for LXR, whose
activation affords atheroprotection (Michael et al., 2012; Im and
Osborne, 2011). Having previously identified 27HC to be an
estrogen receptor (ER) ligand (Umetani and Shaul, 2011), the
hypothesis that 27HC impacts atherosclerosis via ER-depen-
dent processes was then tested. The cellular targets of 27HC
potentially operative in the promotion of atherosclerosis by the
oxysterol were also investigated, and the underlying mecha-
nisms were delineated.
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Figure 1. Lipid and 27HC Status of Wild-
Type, cyp7b1–/–, apoe–/–, and apoe–/–;
cyp7b1–/– Male and Female Mice
(A and B) At 12 months of age, plasma cholesterol
(A) and 27HC concentrations (B) were measured
in intact mice. Values are mean ± SEM; n = 5–10;
*p < 0.05 versus WT, yp < 0.05 versus apoe/.
(C and D) Lipid profiles were also evaluated in
samples pooled from two male (C) or two female
(D) mice.
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Impact of 27HC on Atherosclerosis
To determine how an increase in endogenous 27HC impacts
atherosclerosis, lesions were evaluated at 12 months of age in
intact male and female apoe+/+;cyp7b1+/+ wild-type, cyp7b1/,
apoe/, and apoe/;cyp7b1/littermates. Total cholesterol
was similar in cyp7b1/ mice versus wild-type mice, and pre-
dictably, plasma 27HC was elevated in cyp7b1/ (Figures 1A
and 1B). Lipid profiles were normal in cyp7b1/ mice (Figures
1C and 1D). In apoe/, predictably both plasma cholesterol
and 27HC were elevated compared to wild-type, and the lipid
profiles displayed elevated very-low-density lipoprotein (VLDL),
intermediate-density lipoprotein (IDL)/low-density lipoprotein
(LDL) fractions, and decreased high-density lipoprotein (HDL)
cholesterol. In apoe/;cyp7b1/, total plasma cholesterol
was similar to that in apoe/, and plasma 27HC was greater
than that in either cyp7b1/ or apoe/ single knockout mice.
Plasma triglyceride was predictably elevated by apoe deletion
and similar in apoe/ and apoe/;cyp7b1/ mice (Table S1).
Interestingly, lipid profiles in apoe/;cyp7b1/ mice revealed
lower IDL/LDL cholesterol than those in apoe/ mice. Thus,
comparisons between wild-type and cyp7b1/ determine the
impact of 27HC in the setting of normal cholesterol status, and
comparisons between apoe/ and apoe/;cyp7b1/ indicate
how 27HC influences atherosclerosis in the setting of compara-
ble hypercholesterolemia.
In the aortic root at 12months of age, there was increased lipid
deposition in the medial layer in cyp7b1/ compared with wild-
type mice (Figures 2A and 2B), and predictably, atherosclerotic
lesions were prevalent in apoe/. Revealing the impact of
27HC in the setting of hypercholesterolemia, atherosclerotic le-
sions were larger in apoe/;cyp7b1/ than in apoe/ mice.
In comparisons between sexes, apoe/ males had greater
lesions than females, mimicking the previous observation ofCell Metabolism 20, 172gender differences likely related to pro-
tective actions of estrogen (Nofer, 2012).
In contrast, in apoe/;cyp7b1/, lesion
size was comparable in males and fe-
males. In analyses of aortic root lesions
at 6 months of age (Figure S1 and Table
S2, available online), lesions were greater
in apoe/;cyp7b1/ versus apoe/ in
both males and females, despite lower
plasma cholesterol in double knockouts.
Lesion abundance in the aorta was
evaluated at 12 months of age (Figures2C and 2D), and paralleling the findings in the aortic root, en
face lesions were larger in apoe/;cyp7b1/ than in apoe/
in both males and females. The cumulative findings at 6 and
12months of age indicate that under normocholesterolemic con-
ditions, elevations in 27HC cause increased lipid deposition in
the media of the proximal aorta, and in the setting of hypercho-
lesterolemia and independent of adverse impact on circulating
lipids, elevated 27HC causes a progressive, marked increase
in atherosclerotic lesion development. In addition, they reveal
that the capacity of 27HC to promote atherosclerosis is compa-
rable in male and female mice.
Impact of 27HC on Estrogen-Related Atheroprotection
Since oxysterols participate in RCT and are ligands for LXR, and
both mechanisms are atheroprotective (Michael et al., 2012; Im
and Osborne, 2011), the worsening of atherosclerosis by 27HC
does not likely entail these processes. Having previously discov-
ered 27HC to be anER ligand (Umetani et al., 2007), we next eval-
uated how 27HC impacts estrogen-related atheroprotection in
ovariectomized female apoe/ and apoe/;cyp7b1/ mice.
Lipid analyses revealed that in vehicle- and E2-treated mice
receiving 6 mg/day, total cholesterol (Table S3) and IDL and LDL
cholesterol (Figure S2) were actually lower in apoe/;cyp7b1/
versus apoe/ mice. In apoe/, E2 treatment lowered plasma
27HC, whereas there was no impact of E2 on plasma 27HC in
apoe/;cyp7b1/ (Table S3). This is consistent with the previ-
ous observation that E2 upregulates hepatic CYP7B1 expression
(Yamamoto et al., 2006). In vehicle-treated mice, aortic root
lesion area was greater in apoe/;cyp7b1/ versus apoe/
mice (Figure 3). In apoe/, 6 mg/day E2 treatment caused an
approximately 50% decrease in lesion area, and 50 mg/day E2
treatment caused a further decline in lesion area. In contrast, in
apoe/;cyp7b1/, 6 mg/day E2 was not atheroprotective, and
lesion size following 6 mg/day E2 remained far greater in
apoe/;cyp7b1/ than in apoe/. However, E2 at 50 mg/day–182, July 1, 2014 ª2014 Elsevier Inc. 173
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Figure 2. 27HC Increases Atherosclerotic
Lesion Formation
(A and B) Representative images and summary
data for aortic root lesions in intact 12-month-
old wild-type (WT), cyp7b1/, apoe/, and
apoe/;cyp7b1/ male and female mice are
shown in (A) and (B), respectively.
(C and D) Findings for atherosclerotic lesions in the
aortas of male (C) and female (D) mice are pro-
vided. Summary data are provided in scatter plots.
Mean values are indicated by the long horizontal
line, and SEM by the short horizontal line. Related
data are provided in Table S1. *p < 0.05 versusWT,
yp < 0.05 versus apoe/, Dp < 0.05 versus males.
See also Figure S1.
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areas were similar following 50 mg/day E2 in apoe
/;cyp7b1/
and apoe/ mice. Since 27HC and E2 compete for ER binding
(Umetani et al., 2007), the dose-related capacity of E2 to reverse
the exaggerated atherosclerosis caused by elevated endoge-
nous 27HC suggests that the atherogenic effects of 27HC are
related to its function as an ER ligand. In addition, since the
27HC-associated worsening of atherosclerosis is evident in
ovariectomized females and also in males, the adverse impact
of the oxysterol occurs via the direct modulation of ER function
rather than through the antagonism of estrogen action.174 Cell Metabolism 20, 172–182, July 1, 2014 ª2014 Elsevier Inc.Impact of 27HC on Vascular
Inflammation In Vivo
Since inflammation is critically involved in
atherogenesis (Galkina and Ley, 2009;
Libby, 2012) and ER modulate inflamma-
tory processes (Straub, 2007; Arnal et al.,
2009), the impact of 27HC on inflamma-
tion in the atherosclerotic lesions was
evaluated. Mac-3 staining of aortic
root lesions (Figure S3) revealed greater
areas of macrophage accumulation in
apoe/;cyp7b1/ versus apoe/ mice
(Figures S3A and S3B). There was also a
directional change in lesion size relative
to macrophage abundance (p = 0.11) (Fig-
ure S3C), perhaps suggesting greater
macrophage-driven lesion development
in apoe/;cyp7b1/ versus apoe/.
In aortae from 12-month-old males,
macrophage infiltration assessed by
quantifying CD68 transcript abundance
was greater in apoe/;cyp7b1/ versus
apoe/ mice (Figure 4A). Steady-state
mRNA levels for interleukin-6 (IL-6), matrix
metallopeptidase 9 (MMP-9), and tumor
necrosis factor alpha (TNF-a) normalized
to CD68 mRNA were 2.2-, 3.3-, and
2.5-fold greater, respectively, in the aortas
of apoe/;cyp7b1/ versus apoe/
mice (Figures 4B–4D). Plasma TNF-a was
also increased in apoe/;cyp7b1/
versus apoe/ mice (Figure S4A). Thus,
an increase in 27HC in the setting of hypercholesterolemia causes
greater macrophage infiltration and exaggeration of inflammatory
cytokinegeneactivationby themacrophagesor other cell types in
the vascular wall.
To directly evaluate the initiating events by which 27HC poten-
tially drives vascular inflammation in vivo, intravital microscopy
was performed to quantify leukocyte-endothelial adhesion
in the mesenteric microcirculation. Male C57BL/6 mice were
treated daily for 3 days with vehicle or 27HC. On the following
day, they received vehicle or TNF-a to promote inflammation,
endogenous leukocytes were fluorescently labeled by the
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Figure 3. 27HC Attenuates E2-Related Atheroprotection
(A) Representative images of aortic roots in female apoe/ versus
apoe/;cyp7b1/ mice ovariectomized at 12 weeks of age, fed a Western
diet, and treated with vehicle, 6 mg/day E2, or 50 mg/day E2 for 8 weeks.
(B) Summary data are provided in scatter plots. Mean values are indicated by
the long horizontal line, and SEM by the short horizontal line. *p < 0.05 versus
apoe/, yp < 0.05 versus vehicle. See also Figure S2 and Table S3.
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to visualize the leukocytes and quantify their velocity. Treatment
with TNF-a predictably lowered leukocyte velocity, and 27HC
caused a comparable decrease in velocity (Figure 4 and Movies
S1, S2, S3, and S4). 27HC also lessened velocity in mice that
received TNF-a cotreatment. These collective findings indicate
that 27HC promotes proinflammatory processes in the vascula-
ture, including causing marked enhancement of leukocyte-
endothelial adhesion under normocholesterolemic conditions.
Impact of 27HC on Monocytes/Macrophages and
Endothelial Cells
To determine the cellular targets of 27HC participating in its pro-
motion of vascular inflammation, experiments were performed
in cell culture. In peritoneal macrophages from wild-type mice,
27HC upregulated TNF-a mRNA by almost 6-fold and IL-1b
mRNA and IL-6 mRNA by 3-fold (Figures 5A–5C); these
responses did not occur in macrophages devoid of ERa, and
they were present in macrophages lacking both LXRa and
LXRb (Figures S4B–S4D). The changes in cytokine transcript
abundance were associated with increases in cytokine produc-
tion (Figures S4E–S4G). Thus, 27HC promotes the expression
of proinflammatory genes in macrophages through ERa-de-
pendent, LXR-independent processes.
To assess direct 27HC action on endothelial cells, bovine
aortic endothelial cells (BAECs) were treated for 24 hr, and endo-thelial cell-monocyte adhesion assays were then performed.
27HC promotedmonocyte-endothelial cell adhesion (Figure 5D),
and the increase in adhesion was fully prevented by the ERa
antagonist methyl-piperidino-pyrazole (MPP) (Figure 5E) or by
siRNA-based knockdown of endothelial cell ERa (Figure 5F).
To determine if 27HC also has direct action on monocytes/
macrophages that promotes adhesion, additional experiments
were performed following 24 hr treatment of the monocytes
with 27HC. Again 27HC promoted monocyte-endothelial cell
adhesion, and MPP blunted the response (Figure 5G). Thus, in
both endothelial cells and monocytes/macrophages, ERa mod-
ulation by 27HC in the absence of estrogen enhances diverse
proinflammatory processes.
27HC Activation of NF-kB
To further interrogate the proinflammatory actions of 27HC and
compare the effects of 27HC with those of E2, NF-kB activation
in endothelial cells was evaluated. Although the overall impact of
NF-kB activation on atherosclerosis is complex, studies in mice
have demonstrated that NF-kB activation in endothelial cells
plays a major role in the pathogenesis of the disorder (Gareus
et al., 2008). Under quiescent conditions, inactive NF-kB is
bound to IkBa in the cytoplasm, and inflammatory stimuli induce
the phosphorylation of IkBa at Ser32 leading to its ubiquitination
and proteasomal degradation, releasing NF-kB to translocate to
the nucleus to drive the expression of target genes (Mercurio
and Manning, 1999). E2 inhibits NF-kB activation in both endo-
thelial and nonendothelial cells (Simoncini et al., 2000; Ghisletti
et al., 2005), and a number of mechanisms have been impli-
cated, including direct protein-protein interactions between
ER and NF-kB, sharing of coactivators, inhibition of NF-kB
DNA binding, increased expression of IkBa, and decreased
IkBa Ser32 phosphorylation (Stein and Yang, 1995; Ray et al.,
1994; Ray et al., 1997; Deshpande et al., 1997; Sun et al.,
1998; Harnish et al., 2000; Speir et al., 2000; Simoncini
et al., 2000). Using lipopolysaccharide (LPS) as a positive con-
trol, we evaluated NF-kB activation in endothelial cells by immu-
nocytochemical localization of the p65 subunit and found that
27HC caused NF-kB activation (Figure 6A). In contrast, E2 abro-
gated LPS-induced p65 nuclear translocation (Figure S5). Thus,
the two ER ligands, 27HC and E2, have entirely opposite effects
on the activation of NF-kB.
To determine how 27HC activates NF-kB in endothelial cells,
its impact on IkBa protein abundance was evaluated. 27HC
treatment caused IkBa abundance to fall to 30% of basal levels
by 30 min (Figure 6B). Dose-response studies revealed that the
effect is apparent at a threshold concentration of 27HC of
0.1 mM (Figure 6C). In contrast to 27HC, E2 did not cause a fall
in IkBa abundance, and its addition to 27HC-treated cells
prevented the 27HC-induced decline in IkBa (Figure 6D). As
importantly, whereas LPS-induced IkBa degradation was not
prevented by ERa deletion, the degradation caused by 27HC
was fully reversed by silencing of the receptor (Figure 6E).
Thus, 27HC uniquely activates NF-kB in endothelial cells, and
this is related to ERa-dependent promotion of IkBa degradation.
Recognizing that NF-kB activation is often modulated by
mitogen-activated protein kinases (MAPKs) (Kaminska, 2005;
Hoesel and Schmid, 2013), to elucidate the basis for 27HC action
on IkBa, the relative levels of activating phosphorylation ofCell Metabolism 20, 172–182, July 1, 2014 ª2014 Elsevier Inc. 175
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Figure 4. 27HC Promotes Vascular Inflam-
mation
(A) Macrophage infiltration was compared in
the aortas of 12-month-old male apoe/ versus
apoe/;cyp7b1/ mice by quantifying transcript
abundance for CD68.
(B–D) Steady-state mRNA levels for IL-6 (B), MMP-
9 (C), and TNF-a (D) normalized to CD68 expres-
sion were also compared. In (A)–(D), values are
mean ± SEM; n = 4–6; *p < 0.05 versus apoe/.
(E–I) 27HC promotes leukocyte-endothelial cell
adhesion in vivo. Male C57BL/6 mice were treated
with vehicle or 27HC, followed by vehicle or TNF-a,
and intravital microscopy was then performed to
evaluate leukocyte-endothelial cell adhesion in the
mesenteric microcirculation. Representative still
images are shown for mice treated with vehicle
(Veh) (E), 27HC (F), TNF-a (G), or TNF-a plus 27HC
(H). Summary data are provided in (I). Values are
mean ± SEM; n = 7–9; *p < 0.05 versus no 27HC,
yp < 0.05 versus no TNF-a. See also Figures S3
and S4A and Movies S1, S2, S3, and S4.
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Jun N-terminal kinase (JNK) were evaluated in 27HC-treated
endothelial cells. Responses to LPSwere studied in comparison.
Both 27HC and LPS caused a decline in IkBa and also an in-
crease in IkBa Ser32 phosphorylation (Figure 6F). Both 27HC
and LPS also caused an increase in Erk1,2 phosphorylation
and an increase in JNK phosphorylation, whereas only LPS
yielded an increase in p38MAPK phosphorylation. To determine
the potential role of MAPK activation by 27HC in the actions of
the oxysterol on IkBa, MAPK inhibitors were employed. Whereas
the MEK inhibitor PD98059 and the JNK inhibitor SP600125 pre-
vented the decline in IkBa abundance caused by 27HC, either
alone or in combination, the p38MAPK inhibitor SB203580 had
no effect (Figure 6G). Thus, Erk1,2 and JNK activation are
required for 27HC engagement of ERa in endothelial cells to pro-
mote the degradation of IkBa and thereby activate the NF-kB
pathway.176 Cell Metabolism 20, 172–182, July 1, 2014 ª2014 Elsevier Inc.ER and 27HC Exacerbation of
Inflammation and Atherosclerosis
Having determined that ERa uniquely
modulates the direct proinflammatory ac-
tions of 27HC on cultured monocytes/
macrophages and endothelial cells, the
role of ER in 27HC-induced enhancement
of leukocyte-endothelial cell adhesion
was studied in vivo by intravital micro-
scopy (Figure 7A) using the ER-specific
antagonist ICI 182,780 (Chambliss et al.,
2010). The treatment of healthy male
mice with ICI 182,780 caused a decrease
in leukocyte velocity (Figure S6A),
indicating that ER antagonize adhesion
in vivo under basal conditions. A dose of
ICI 182,780 below the threshold that
promotes adhesion was then employed
in studies of male mice administered
27HC. The decline in leukocyte velocityindicative of an enhancement in adhesion by 27HCwas fully pre-
vented by ICI 182,780 (Figure 7A). When combined with the ob-
servations made in cell culture (Figure 5), these in vivo findings
indicate that the proinflammatory actions of 27HC on the
vascular wall occur via ER-dependent mechanisms, that the ef-
fects of 27HC are not merely via antagonism of estrogen action,
and that instead the oxysterol is directly modifying both leuko-
cyte and endothelial cell functions independent of steroid hor-
mone action.
Whereas ERa classically mediates antiatherosclerotic pro-
cesses (Ribas et al., 2011; Billon-Gale´s et al., 2009), the potential
proatherosclerotic role of the receptor was then interrogated
in studies of apoe/ versus apoe/;era/ male mice adminis-
tered vehicle or 27HC for 6 weeks. Serum 27HC levels in the
vehicle versus 27HC-treated apoe/ mice were 1,022 ± 68 and
1,840 ± 188 ng/ml, respectively (p < 0.05), and in vehicle versus
27HC-treated apoe/;era/ mice, they were 955 ± 133 and
Figure 5. 27HC Has Direct Proinflammatory
Actions on Monocytes/Macrophages and
Endothelial Cells Mediated by ERa
(A–C) Peritoneal macrophages from wild-type
(WT) or era/ mice were treated with vehicle
(Veh) or 27HC for 20 hr, and transcript abundance
for TNF-a (A), IL-1b (B), or IL-6 (C) was evaluated.
n = 3.
(D–F) Bovine aortic endothelial cells were treated
with vehicle or 27HC, and the adhesion of added
U937 cells was evaluated. The dose response to
27HC was assessed (n = 7) (D), and the involve-
ment of endothelial cell ERawas determined using
the selective ERa antagonist MPP (n = 4) (E) or
siRNA knockdown of the receptor (n = 4) (F).
Effective loss of ERa protein with siRNA knock-
down is shown in the inset.
(G) The impact of 27HC on adhesion-promoting
mechanisms in monocytes was determined in
U937 cells treated 18 hr with vehicle or 27HC, with
or without MPP added, prior to their addition to
endothelial cells (n = 6). Values are mean ± SEM
expressed relative to vehicle treatment; *p < 0.05
versus vehicle. See also Figures S4B–S4G.
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27-Hydroxycholesterol Promotes Atherosclerosis2,228± 332ng/ml, respectively (p < 0.05). The lipid profiles in both
genotype groups were unaffected by 27HC (Figures S6B and
S6C). Whereas 27HC administration caused a doubling in lesion
area in apoe/ (Figures 7B and 7C), it had no impact in
apoe/;era/mice (Figures 7D and 7E). These findings parallel
thoseobtainedwithgeneticdeletionofcyp7b1 (Figure2), and they
demonstrate that the proatherosclerotic processes are mediated
by 27HC action on ERa. Thus, in contrast to the E2-ERa tandem,
the ligand-receptor partnership between ERa and its nonaromat-
ized ligand 27HC is uniquely proatherogenic.
DISCUSSION
Circulating levels of oxysterols are predictably elevated with hy-
percholesterolemia, and oxysterols are concentrated in athero-Cell Metabolism 20, 172sclerotic lesions (Brown and Jessup,
1999). How oxysterols, including the
most abundant oxysterol 27HC, impact
vascular disease has been enigmatic
because of the close correlation between
27HC and cholesterol abundance (Tonto-
noz and Mangelsdorf, 2003). In the pre-
sent work, we employed both genetic
and pharmacologic manipulations in
mice to segregate the actions of
cholesterol and 27HC. We discovered
that atherosclerosis is promoted in
both males and females by elevations in
27HC independent of changes in choles-
terol and that the proatherogenic actions
of 27HC are uniquely mediated by ERa.
Thus, in addition to the adverse impact
of 27HC on bone mineralization and
breast cancer (Wu et al., 2013; Nelson
et al., 2013), it is now apparent that theonly other known endogenous ER ligand besides estrogen nega-
tively affects cardiovascular health.
Inflammation is critically involved in atherogenesis (Galkina
and Ley, 2009; Libby, 2012), and we discovered that 27HC in-
vokes proinflammatory processes in vascular cells both in vitro
and in vivo. Macrophage accumulation in the vascular wall was
increased by 27HC, proinflammatory genes were upregulated,
and plasma TNF-a was elevated. Importantly, we demonstrated
that leukocyte-endothelial cell adhesion, which is a key early
event in the pathogenesis of atherosclerosis (Libby et al.,
2006), is potently promoted in vivo by elevations in 27HC even
in the setting of normocholesterolemia. Studies of cultured
monocytes/macrophages and endothelial cells then revealed
that both cell types are targets of the proinflammatory actions
of 27HC and that these effects are ERa dependent. In parallel,–182, July 1, 2014 ª2014 Elsevier Inc. 177
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Figure 6. 27HC Promotes IkBa Degradation and Activates NF-kB in Endothelial Cells via ERa, Erk1,2-, and JNK-Dependent Processes
(A) Using immunofluorescence, the subcellular distribution of the NF-kB subunit p65 was evaluated in endothelial cells treated with vehicle, LPS (100 nM), or
27HC (10 mM). p65 is shown in green, and nuclei stained with DAPI. Values are mean ± SEM; n = 10–18; *p < 0.05 versus vehicle.
(B and C) The impact of 27HC on IkBa abundance was evaluated in cells treated for 0–120 min with 10 mM 27HC (B) or in cells treated for 30 min with 0–10 mM
27HC (C). In (B) and (C), values are mean ± SEM; n = 6–9; *p < 0.05 versus vehicle.
(legend continued on next page)
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27-Hydroxycholesterol Promotes AtherosclerosisER loss of function prevented the in vivo enhancement of leuko-
cyte-endothelial cell adhesion by 27HC and also the worsening
of atherosclerosis by the oxysterol. Although the impact of
NF-kB activation on atherosclerosis is complex, it has been
convincingly demonstrated in apoe/ mice that NF-kB activa-
tion in endothelial cells plays a major role in atherogenesis (Gar-
eus et al., 2008). We therefore focused further mechanistic
studies of the basis for 27HC activation of NF-kB on endothelial
cells and found that 27HC promotes NF-kB nuclear transloca-
tion, whereas E2 is inhibitory, and that the activation of NF-kB
by 27HC is related to ERa-dependent, Erk1,2 and JNK-depen-
dent IkBa protein degradation. The biochemical basis for
27HC-ERa modulation of MAPKs and other processes that
lead to IkBa degradation can now be pursued.
In addition to demonstrating proinflammatory actions of 27HC
directly mediated by ERa in the absence of E2 in cell culture, and
proatherogenic, ERa-dependent effects of 27HC in male mice,
competing actions of the oxysterol and estrogen on atheroscle-
rosis were observed in ovariectomized female mice. 27HC
potently antagonized the atheroprotection afforded by E2 when
the hormone was replaced at physiologic concentrations, and it
was only at superphysiologic levels that E2 was atheroprotective
in the setting of elevated 27HC. These findings lend further sup-
port to theconclusion that theproatherosclerotic actionsof 27HC
are ER dependent. In addition, they have potentially important
clinical implications regarding cardiovascular health and itsman-
agement in women. The risk of coronary heart disease in women
increases dramatically after menopause (Lloyd-Jones et al.,
2009), and there is considerable evidence that hormone replace-
ment therapy (HRT) with estrogen is not beneficial and instead is
possibly harmfulwhengiven towomenyearsafter theyhavegone
through menopause (Mendelsohn and Karas, 2005; Clarkson
et al., 2013). Although numerous mechanisms may underlie the
change in response to HRT with age, existing atherosclerosis
likely plays a critical role (Mendelsohn and Karas, 2005; Karas,
2004; Wagner and Clarkson, 2005; Dubey et al., 2005). Since
27HC levels rise with age and 27HC is abundant in atheroscle-
rotic lesions (Brown and Jessup, 1999; Burkard et al., 2007),
our current findings suggest that the potential vascular benefits
of either endogenous or exogenous estrogen may be attenuated
in older women by the actions of 27HC.
Now knowing that 27HC promotes atherosclerosis indepen-
dent of changes in cholesterol, the processes that govern
27HC abundance can potentially be targeted to provide thera-
peutic opportunities independent of the multiple strategies
aimed at cholesterol lowering. The enzyme that synthesizes
27HC, CYP27A1, is normally abundant in the liver and also
constitutively expressed in normal arterial wall, and it is upregu-
lated and abundant in atherosclerotic lesions (Crisby et al., 1997;
Shanahan et al., 2001; Russell, 2000). The cellular or tissue sour-
ce(s) of 27HC that is important to the contribution of the oxysterol(D) The effects of 27HC (10 mM), E2 (10 nM), or the combination of 27HC and E2
(E) The effects of 27HC (10 mM) or LPS (100 ng/ml) on IkBa abundance were com
targeting ERa.
(F) MAPK activation in response to 27HC (10 mM) or LPS (100 ng/ml) treatment for
Erk1,2, p38MAPK, and JNK. IkBa Ser32 phosphorylation and total protein abund
(G) The effect of 27HC (10 mM) on IkBa abundancewas compared over 30min in ce
(10 mM), SP600125 (10 mM), or PD98059 plus SP600125. See also Figure S5.to atherogenesis has yet to be identified. This consideration, as
well as the numerous other roles of CYP27A1 and 27HC, such as
in bile acid synthesis and RCT (Brown and Jessup, 1999;
Li-Hawkins et al., 2000; Russell, 2000; Tontonoz and Mangels-
dorf, 2003), need to be carefully addressed in order to optimally
contemplate a mode of CYP27A1 loss of function as a strategy
for possible atheroprotection. CYP7B1, which metabolizes
27HC, is also normally highly abundant in the liver (Russell,
2003). Complementary to possibly targeting CYP27A1 to
lower 27HC synthesis, whether enhancing its metabolism by
CYP7B1 lessens atherosclerosis in the setting of hypercholes-
terolemia now also deserves investigation.
In addition to lowering 27HC abundance for therapeutic gain,
impacting its mechanisms of action can be contemplated. Since
we previously showed that 27HC binding cause changes in ERa
conformation (DuSell et al., 2008), the ER-dependent actions of
the oxysterol can potentially be selectively inhibited to lessen its
adverse influence on vascular disease while retaining potential
beneficial effects of ER activation by estrogen.
Strategies to lower cholesterol, such as the use of statins, have
had a dramatic impact on cardiovascular health. However, there
continues to be a need for complementary approaches to com-
bat atherosclerosis, and these have been somewhat limited in
number or are accompanied by complications or unresolved
questions, as is the case with HDL-targeted therapies and HRT
(Phan and Toth, 2013; Larach et al., 2012; Santen et al., 2010).
At the same time that insights havebeengainedabout thebiology
of oxysterols andnuclear receptors, thediscovery that 27HCpro-
motes atherosclerosis through unique ERa-mediated mecha-
nisms may afford unique opportunities for therapy development.
EXPERIMENTAL PROCEDURES
Animal and Cell Culture Models
Wild-type, cyp7b1/, apoe/, and apoe/;cyp7b1/ littermates were
generated by crossing cyp7b1/mice (originally from David Russell, Depart-
ment of Molecular Genetics, UT Southwestern) (Li-Hawkins et al., 2000) with
apoe/ mice (The Jackson Laboratory). All four genotype groups were fed
standard chow. E2-related atheroprotection was studied in apoe
/ and
apoe/;cyp7b1/ female mice ovariectomized at 12 weeks of age, and
then they were placed on a Western diet (21% milk fat, 0.2% cholesterol,
Teklad 88137) and treated with vehicle or E2 at 6 mg/day or 50 mg/day using
subcutaneously implanted pellets (Innovative Research of America). Athero-
sclerotic lesions were evaluated 8weeks later. To determine the effect of exog-
enous 27HC on atherogenesis and the role of ERa, 12-week-old male apoe/
or apoe/;era/ mice were treated with vehicle or 27HC (20 mg/kg body
weight) by subcutaneous injection every 2 days for 6 weeks, and lesions
were then evaluated. The 27HC was dissolved in 30% (2-hydroxypropyl)-
b-cyclodextrin solution, and the same solution served as the control treatment.
All animal studies were approved by the Institutional Animal Care and Use
Committee at UT Southwestern.
To investigate processes in monocytes/macrophages, studies were per-
formed in either macrophages isolated from the mouse peritoneum using thi-
oglycolate (Venkateswaran et al., 2000) or the monocyte cell line U937. Miceon IkBa abundance were compared over 30 min.
pared over 30 min in cells previously transfected with control siRNA or siRNA
0–120min was evaluated by immunoblot analyses for phosphorylated and total
ance were also assessed.
lls coincubatedwith vehicle or theMAPK inhibitors PD98059 (1 mM), SB203580
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Figure 7. ER Mediates the Proinflammatory and Proatherosclerotic
Actions of 27HC In Vivo
(A) Leukocyte-endothelial adhesion was evaluated by intravital microscopy in
wild-typemale mice administered vehicle or 27HCwithout or with cotreatment
with ICI 182,780. Values are mean ± SEM; n = 7–11; *p < 0.05 versus no 27HC,
yp < 0.05 versus no ICI 182,780.
(B–E) The impact of 27HC administration on atherosclerosis was evaluated
in apoe/ (B and C) or apoe/;era/ male mice (D and E). Representative
aortic root lesions for vehicle or 27HC-treated mice are shown in (B) and (D),
and summary data (mean ± SEM) are provided in (C) (n = 12–13) and (E) (n = 7);
*p < 0.05 versus vehicle. See also Figure S6.
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kawa et al., 2013). Processes in endothelial cells were interrogated in primary
bovine aortic endothelial cells (BAECs) (Chambliss et al., 2010). For in vitro
studies, 27HC was diluted from a 10 mM ethanol solvent stock directly into
assay medium, and identical concentrations of ethanol were present under
control conditions.
Cholesterol, Triglyceride, 27HC, and Estradiol Analyses
Plasma total cholesterol, 27HC, and E2 concentrations were evaluated as
previously described (Umetani et al., 2007). Plasma triglyceride levels were
measured by colorimetric enzymatic assay (Roche Diagnostics). Aorta choles-
terol and triglyceride content were assessed following ether lipid extraction
(Kalaany et al., 2005). Plasma lipid profiles were obtained by column fraction-
ation and measurements of fraction cholesterol content on pooled samples
from two or three mice (Kawashiri et al., 2001).
Quantitative RT-PCR
Transcript abundance for IL-6, IL-1b, MMP-9, TNF-a, CD68, or ERa was eval-
uated inmouse aorta or cultured cells by quantitative RT-PCR using previously
described approaches (Bookout andMangelsdorf, 2003; Umetani et al., 2007).
Cytokine Measurements
Plasma TNF-a levels and TNF-a, IL-6, and IL-1b concentrations in cell super-
natants following vehicle versus 27HC treatment were measured using the
DuoSet ELISA System (R&D Systems).
Assessment of Atherosclerosis
Atherosclerotic lesions were evaluated in a blinded fashion (Bourassa et al.,
1996). Mice were anesthetized with avertin and killed, blood was obtained
for analyses, and perfusion fixation was performed. The heart and aorta
were removed, the heart and proximal aorta were embedded in OCT, serial
frozen sections (10 mm) of the aortic root were obtained, and four to six sec-
tions per aorta were processed. To evaluate atherosclerotic lesions in en
face preparations of the aorta, using a dissecting microscope, the adventitial
fat was removed and the aorta was opened longitudinally and pinned onto a
silicon bed. Lipid staining was performed with Sudan IV (Bourassa et al.,
1996). To evaluate macrophage infiltration in the aortic root, immunohisto-
chemical analysis was done with anti-Mac-3 antibody (BD Pharmingen).
Images were captured and areas were determined using Image-Pro Plus soft-
ware (Tangirala et al., 1999; Reddick et al., 1994).
Intravital Microscopy for Quantification of Leukocyte-Endothelial
Adhesion
Leukocyte-endothelial adhesion was evaluated as described previously (Ra-
mesh et al., 2011). Briefly, 5- to 7-week-old male mice were subcutaneously
injected with vehicle or 27HC (20 mg/kg body weight) daily for 3 days, and
on the following day, they received an intraperitoneal (i.p.) injection of vehicle
or TNF-a (0.3 mg). The dose of 27HC used yields serum 27HC concentrations
of 150–200 ng/ml. Vehicle versus TNF-a treatment was employed to evaluate
the impact of 27HC on adhesion under basal conditions and also in the setting
of elevated adhesion. At 4 hr after vehicle or TNF-a treatment, the mice were
prepared for intravital microscopy. Endogenous leukocytes were fluorescence
labeled by injection of the mice with Rhodamine-6G (100 ml of 0.05% solution
given by optic vascular plexus), and themesentery was exposed for the obser-
vation and recording of images of leukocyte adhesion and rolling using a
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cyte rolling was calculated using Image-Pro v.6.2 (Wang et al., 2012). In addi-
tional studies, mice were administered vehicle or 27HC, and also vehicle or the
ER antagonist ICI 182,780 (5 mg) given subcutaneously 48 hr, 24 hr, and 4 hr
prior to study.
Endothelial Cell-Monocyte Adhesion Assays and NF-kB Activation
The adhesion of U937 monocytes to monolayers of BAECs was evaluated as
previously reported (Umetani et al., 2000). Select experiments were done in the
absence versus presence of the selective ERa antagonist methyl-piperidino-
pyrazole (MPP, 106M) (Sun et al., 2002). In additional studies, U937 cells,
and not BAECs, were treated with vehicle versus 27HC for 24 hr prior to inclu-
sion in the adhesion assay.
To evaluate NF-kB activation in endothelial cells, NF-kB p65 subunit intra-
cellular localization was assessed by immunocytochemistry (Simoncini et al.,
2000; Noursadeghi et al., 2008). The relative distribution of p65 in nucleus
versus cytoplasm was quantified by image analysis.
Immunoblot Analyses
ERa protein abundance in endothelial cells was assessed by immunoblot anal-
ysis using mouse monoclonal antibody F-10 (sc-8002, Santa Cruz Biotech-
nology). Total IkBa abundance and relative IkBa Ser32 phosphorylation in
endothelial cells were evaluated by immunoblot analyses with anti-ikBa anti-
body (Cell Signaling Technology), anti-ikBa phospho-Ser32 antibody (Cell
Signaling Technology), and anti-actin antibody (Santa Cruz Biotechnology).
In selected experiments, cells were treated with PD98059 (1 mM), SB203580
(10 mM), or SP600125 (10 mM; Sigma-Aldrich) to evaluate the roles of Erk1,2,
p38MAPK, or JNK, respectively, in the modulation of IkBa. MAPK activation
was evaluated by immunoblotting using antibodies against phospho-Thr202/
Tyr204 Erk1,2, phospho-Thr180/Tyr182 p38MAPK, or phospho-Thr183/
Tyr185 JNK or the respective total proteins (Cell Signaling Technology).
Statistical Analysis
All data are expressed as mean ± SEM. Two-tailed Student’s t test or ANOVA
was used to assess differences between two groups or among more than two
groups, respectively, with Newman-Keuls post hoc testing following ANOVA.
p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, three tables, and four movies
and can be found with this article online at http://dx.doi.org/10.1016/j.cmet.
2014.05.013.
ACKNOWLEDGMENTS
This work was supported by National Institutes of Health grants HL087564
(P.W.S.), P03DK079328 (M.U.), and T32 HL098040 (P.G.); American Diabetes
Association Grant 7-11-JF-46 (M.U.); and by the Associates First Capital Cor-
poration Distinguished Chair in Pediatrics (P.W.S.).
Received: September 6, 2013
Revised: February 11, 2014
Accepted: May 5, 2014
Published: June 19, 2014
REFERENCES
Arnal, J.F., Laurell, H., Fontaine, C., Billon, A., Calippe, B., Lenfant, F., and
Gourdy, P. (2009). Estrogen receptor actions on vascular biology and inflam-
mation: implications in vascular pathophysiology. Climacteric 12 (Suppl 1 ),
12–17.
Billon-Gale´s, A., Fontaine, C., Douin-Echinard, V., Delpy, L., Berges, H.,
Calippe, B., Lenfant, F., Laurell, H., Gue´ry, J.C., Gourdy, P., and Arnal, J.F.
(2009). Endothelial estrogen receptor-alpha plays a crucial role in the athero-
protective action of 17beta-estradiol in low-density lipoprotein receptor-defi-
cient mice. Circulation 120, 2567–2576.Bookout, A.L., and Mangelsdorf, D.J. (2003). Quantitative real-time PCR pro-
tocol for analysis of nuclear receptor signaling pathways. Nucl. Recept. Signal.
1, e012.
Bourassa, P.A., Milos, P.M., Gaynor, B.J., Breslow, J.L., and Aiello, R.J. (1996).
Estrogen reduces atherosclerotic lesion development in apolipoprotein E-defi-
cient mice. Proc. Natl. Acad. Sci. USA 93, 10022–10027.
Brown, A.J., and Jessup, W. (1999). Oxysterols and atherosclerosis.
Atherosclerosis 142, 1–28.
Burkard, I., von Eckardstein, A., Waeber, G., Vollenweider, P., and Rentsch,
K.M. (2007). Lipoprotein distribution and biological variation of 24S- and
27-hydroxycholesterol in healthy volunteers. Atherosclerosis 194, 71–78.
Chambliss, K.L., Wu, Q., Oltmann, S., Konaniah, E.S., Umetani, M., Korach,
K.S., Thomas, G.D., Mineo, C., Yuhanna, I.S., Kim, S.H., et al. (2010). Non-
nuclear estrogen receptor alpha signaling promotes cardiovascular protection
but not uterine or breast cancer growth in mice. J. Clin. Invest. 120, 2319–
2330.
Clarkson, T.B., Mele´ndez, G.C., and Appt, S.E. (2013). Timing hypothesis
for postmenopausal hormone therapy: its origin, current status, and future.
Menopause 20, 342–353.
Crisby, M., Nilsson, J., Kostulas, V., Bjo¨rkhem, I., and Diczfalusy, U. (1997).
Localization of sterol 27-hydroxylase immuno-reactivity in human atheroscle-
rotic plaques. Biochim. Biophys. Acta 1344, 278–285.
Deshpande, R., Khalili, H., Pergolizzi, R.G., Michael, S.D., and Chang, M.D.
(1997). Estradiol down-regulates LPS-induced cytokine production and
NFkB activation in murine macrophages. Am. J. Reprod. Immunol. 38, 46–54.
Dubey, R.K., Imthurn, B., Barton, M., and Jackson, E.K. (2005). Vascular
consequences of menopause and hormone therapy: importance of timing of
treatment and type of estrogen. Cardiovasc. Res. 66, 295–306.
DuSell, C.D., Umetani, M., Shaul, P.W., Mangelsdorf, D.J., and McDonnell,
D.P. (2008). 27-hydroxycholesterol is an endogenous selective estrogen
receptor modulator. Mol. Endocrinol. 22, 65–77.
Galkina, E., and Ley, K. (2009). Immune and inflammatory mechanisms of
atherosclerosis (*). Annu. Rev. Immunol. 27, 165–197.
Gareus, R., Kotsaki, E., Xanthoulea, S., van der Made, I., Gijbels, M.J.,
Kardakaris, R., Polykratis, A., Kollias, G., de Winther, M.P., and Pasparakis,
M. (2008). Endothelial cell-specific NF-kappaB inhibition protects mice from
atherosclerosis. Cell Metab. 8, 372–383.
Ghisletti, S., Meda, C., Maggi, A., and Vegeto, E. (2005). 17beta-estradiol
inhibits inflammatory gene expression by controlling NF-kappaB intracellular
localization. Mol. Cell. Biol. 25, 2957–2968.
Harnish, D.C., Scicchitano, M.S., Adelman, S.J., Lyttle, C.R., and
Karathanasis, S.K. (2000). The role of CBP in estrogen receptor cross-talk
with nuclear factor-kappaB in HepG2 cells. Endocrinology 141, 3403–3411.
Hoesel, B., and Schmid, J.A. (2013). The complexity of NF-kB signaling in
inflammation and cancer. Mol. Cancer 12, 86.
Im, S.S., and Osborne, T.F. (2011). Liver x receptors in atherosclerosis and
inflammation. Circ. Res. 108, 996–1001.
Ishikawa, T., Yuhanna, I.S., Umetani, J., Lee, W.R., Korach, K.S., Shaul, P.W.,
and Umetani, M. (2013). LXRb/estrogen receptor-a signaling in lipid rafts
preserves endothelial integrity. J. Clin. Invest. 123, 3488–3497.
Kalaany, N.Y., Gauthier, K.C., Zavacki, A.M., Mammen, P.P., Kitazume, T.,
Peterson, J.A., Horton, J.D., Garry, D.J., Bianco, A.C., and Mangelsdorf,
D.J. (2005). LXRs regulate the balance between fat storage and oxidation.
Cell Metab. 1, 231–244.
Kaminska, B. (2005). MAPK signalling pathways as molecular targets for anti-
inflammatory therapy—from molecular mechanisms to therapeutic benefits.
Biochim. Biophys. Acta 1754, 253–262.
Karas, R.H. (2004). Current controversies regarding the cardiovascular effects
of hormone therapy. Clin. Obstet. Gynecol. 47, 489–499.
Kawashiri, M., Zhang, Y., Usher, D., Reilly, M., Pure´, E., and Rader, D.J. (2001).
Effects of coexpression of the LDL receptor and apoE on cholesterol meta-
bolism and atherosclerosis in LDL receptor-deficient mice. J. Lipid Res. 42,
943–950.Cell Metabolism 20, 172–182, July 1, 2014 ª2014 Elsevier Inc. 181
Cell Metabolism
27-Hydroxycholesterol Promotes AtherosclerosisLarach, D.B., deGoma, E.M., and Rader, D.J. (2012). Targeting high density
lipoproteins in the prevention of cardiovascular disease? Curr. Cardiol. Rep.
14, 684–691.
Li-Hawkins, J., Lund, E.G., Turley, S.D., and Russell, D.W. (2000). Disruption
of the oxysterol 7alpha-hydroxylase gene in mice. J. Biol. Chem. 275,
16536–16542.
Libby, P. (2012). Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc.
Biol. 32, 2045–2051.
Libby, P., Aikawa, M., and Jain, M.K. (2006). Vascular endothelium and
atherosclerosis. Handbook Exp. Pharmacol., (176 Pt 2): 285–306.
Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T.B.,
Flegal, K., Ford, E., Furie, K., Go, A., Greenlund, K., et al.; American Heart
Association Statistics Committee and Stroke Statistics Subcommittee
(2009). Heart disease and stroke statistics—2009 update: a report from the
American Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Circulation 119, 480–486.
Mendelsohn, M.E., and Karas, R.H. (2005). Molecular and cellular basis of
cardiovascular gender differences. Science 308, 1583–1587.
Mercurio, F., and Manning, A.M. (1999). Multiple signals converging on
NF-kappaB. Curr. Opin. Cell Biol. 11, 226–232.
Michael, D.R., Ashlin, T.G., Buckley, M.L., and Ramji, D.P. (2012). Liver
X receptors, atherosclerosis and inflammation. Curr. Atheroscler. Rep. 14,
284–293.
Nelson, E.R., Wardell, S.E., Jasper, J.S., Park, S., Suchindran, S., Howe, M.K.,
Carver, N.J., Pillai, R.V., Sullivan, P.M., Sondhi, V., et al. (2013).
27-Hydroxycholesterol links hypercholesterolemia and breast cancer patho-
physiology. Science 342, 1094–1098.
Nofer, J.R. (2012). Estrogens and atherosclerosis: insights from animal models
and cell systems. J. Mol. Endocrinol. 48, R13–R29.
Noursadeghi, M., Tsang, J., Haustein, T., Miller, R.F., Chain, B.M., and Katz,
D.R. (2008). Quantitative imaging assay for NF-kappaB nuclear translocation
in primary human macrophages. J. Immunol. Methods 329, 194–200.
Phan, B.A., and Toth, P.P. (2013). Is the future of statins aligned with new novel
lipid modulation therapies? Curr. Atheroscler. Rep. 15, 300.
Ramesh, S., Morrell, C.N., Tarango, C., Thomas, G.D., Yuhanna, I.S., Girardi,
G., Herz, J., Urbanus, R.T., de Groot, P.G., Thorpe, P.E., et al. (2011).
Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion
and thrombosis in mice by antagonizing eNOS via b2GPI and apoER2.
J. Clin. Invest. 121, 120–131.
Ray, A., Prefontaine, K.E., and Ray, P. (1994). Down-modulation of interleukin-
6 gene expression by 17 beta-estradiol in the absence of high affinity DNA
binding by the estrogen receptor. J. Biol. Chem. 269, 12940–12946.
Ray, P., Ghosh, S.K., Zhang, D.H., and Ray, A. (1997). Repression of inter-
leukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding
activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen
receptor. FEBS Lett. 409, 79–85.
Reddick, R.L., Zhang, S.H., and Maeda, N. (1994). Atherosclerosis in
mice lacking apo E. Evaluation of lesional development and progression.
Arterioscler. Thromb. 14, 141–147.
Ribas, V., Drew, B.G., Le, J.A., Soleymani, T., Daraei, P., Sitz, D., Mohammad,
L., Henstridge, D.C., Febbraio, M.A., Hewitt, S.C., et al. (2011). Myeloid-spe-
cific estrogen receptor alpha deficiency impairs metabolic homeostasis and
accelerates atherosclerotic lesion development. Proc. Natl. Acad. Sci. USA
108, 16457–16462.
Russell, D.W. (2000). Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta
1529, 126–135.
Russell, D.W. (2003). The enzymes, regulation, and genetics of bile acid syn-
thesis. Annu. Rev. Biochem. 72, 137–174.
Santen, R.J., Allred, D.C., Ardoin, S.P., Archer, D.F., Boyd, N., Braunstein,
G.D., Burger, H.G., Colditz, G.A., Davis, S.R., Gambacciani, M., et al.;182 Cell Metabolism 20, 172–182, July 1, 2014 ª2014 Elsevier Inc.Endocrine Society (2010). Postmenopausal hormone therapy: an Endocrine
Society scientific statement. J. Clin. Endocrinol. Metab. 95 (Suppl 1 ), s1–s66.
Shanahan, C.M., Carpenter, K.L., and Cary, N.R. (2001). A potential role for
sterol 27-hydroxylase in atherogenesis. Atherosclerosis 154, 269–276.
Simoncini, T., Maffei, S., Basta, G., Barsacchi, G., Genazzani, A.R., Liao, J.K.,
and De Caterina, R. (2000). Estrogens and glucocorticoids inhibit endothelial
vascular cell adhesion molecule-1 expression by different transcriptional
mechanisms. Circ. Res. 87, 19–25.
Speir, E., Yu, Z.X., Takeda, K., Ferrans, V.J., and Cannon, R.O., 3rd. (2000).
Competition for p300 regulates transcription by estrogen receptors and nu-
clear factor-kappaB in human coronary smooth muscle cells. Circ. Res. 87,
1006–1011.
Stein, B., and Yang, M.X. (1995). Repression of the interleukin-6 promoter by
estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol. Cell. Biol.
15, 4971–4979.
Straub, R.H. (2007). The complex role of estrogens in inflammation. Endocr.
Rev. 28, 521–574.
Sun, W.H., Keller, E.T., Stebler, B.S., and Ershler, W.B. (1998). Estrogen
inhibits phorbol ester-induced I kappa B alpha transcription and protein
degradation. Biochem. Biophys. Res. Commun. 244, 691–695.
Sun, J., Huang, Y.R., Harrington, W.R., Sheng, S., Katzenellenbogen, J.A., and
Katzenellenbogen, B.S. (2002). Antagonists selective for estrogen receptor
alpha. Endocrinology 143, 941–947.
Tangirala, R.K., Tsukamoto, K., Chun, S.H., Usher, D., Pure´, E., and Rader,
D.J. (1999). Regression of atherosclerosis induced by liver-directed gene
transfer of apolipoprotein A-I in mice. Circulation 100, 1816–1822.
Tontonoz, P., and Mangelsdorf, D.J. (2003). Liver X receptor signaling path-
ways in cardiovascular disease. Mol. Endocrinol. 17, 985–993.
Umetani, M., and Shaul, P.W. (2011). 27-Hydroxycholesterol: the first identi-
fied endogenous SERM. Trends Endocrinol. Metab. 22, 130–135.
Umetani, M., Nakao, H., Doi, T., Iwasaki, A., Ohtaka, M., Nagoya, T., Mataki,
C., Hamakubo, T., and Kodama, T. (2000). A novel cell adhesion inhibitor,
K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines,
acting through the regulation of GATA. Biochem. Biophys. Res. Commun. 272,
370–374.
Umetani, M., Domoto, H., Gormley, A.K., Yuhanna, I.S., Cummins, C.L.,
Javitt, N.B., Korach, K.S., Shaul, P.W., and Mangelsdorf, D.J. (2007). 27-
Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular
effects of estrogen. Nat. Med. 13, 1185–1192.
Venkateswaran, A., Repa, J.J., Lobaccaro, J.M., Bronson, A., Mangelsdorf,
D.J., and Edwards, P.A. (2000). Human white/murine ABC8 mRNA levels are
highly induced in lipid-loaded macrophages. A transcriptional role for specific
oxysterols. J. Biol. Chem. 275, 14700–14707.
Wagner, J.D., and Clarkson, T.B. (2005). The applicability of hormonal effects
on atherosclerosis in animals to heart disease in postmenopausal women.
Semin. Reprod. Med. 23, 149–156.
Wang, X.Q., Nigro, P., World, C., Fujiwara, K., Yan, C., and Berk, B.C. (2012).
Thioredoxin interacting protein promotes endothelial cell inflammation in
response to disturbed flow by increasing leukocyte adhesion and repressing
Kruppel-like factor 2. Circ. Res. 110, 560–568.
Wu, Q., Ishikawa, T., Sirianni, R., Tang, H., McDonald, J.G., Yuhanna, I.S.,
Thompson, B., Girard, L., Mineo, C., Brekken, R.A., et al. (2013). 27-
Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer
growth. Cell Rep 5, 637–645.
Yamamoto, Y., Moore, R., Hess, H.A., Guo, G.L., Gonzalez, F.J., Korach, K.S.,
Maronpot, R.R., and Negishi, M. (2006). Estrogen receptor alpha mediates
17alpha-ethynylestradiol causing hepatotoxicity. J. Biol. Chem. 281, 16625–
16631.
